Sutro Biopharma Receivables 2017-2024 | STRO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Sutro Biopharma receivables from 2017 to 2024. Receivables can be defined as the total amount of collectibles for a company

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Sutro Biopharma receivables from 2017 to 2024. Receivables can be defined as the total amount of collectibles for a company

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$174.8B
Vertex Pharmaceuticals (VRTX)	$133.1B
Gilead Sciences (GILD)	$120.2B
Bristol Myers Squibb (BMY)	$109.8B
Regeneron Pharmaceuticals (REGN)	$91B
CSL (CSLLY)	$90.5B
GSK (GSK)	$75.2B
Alnylam Pharmaceuticals (ALNY)	$35.8B
Argenex SE (ARGX)	$35.6B
BioNTech SE (BNTX)	$26.3B
Biogen (BIIB)	$25.2B
Illumina (ILMN)	$24B
BeiGene (BGNE)	$20B
Moderna (MRNA)	$18B
Incyte (INCY)	$16.1B
Genmab (GMAB)	$15.3B
Vaxcyte (PCVX)	$13.3B
Insmed (INSM)	$13.2B
BioMarin Pharmaceutical (BMRN)	$12.8B
Bio-Techne Corp (TECH)	$12.1B
Sarepta Therapeutics (SRPT)	$11.6B
Exelixis (EXEL)	$10.4B
Revolution Medicines (RVMD)	$10.2B
QIAGEN (QGEN)	$10B
Intra-Cellular Therapies (ITCI)	$9.7B
Exact Sciences (EXAS)	$9.5B
Bio-Rad Laboratories (BIO.B)	$9.4B
Roivant Sciences (ROIV)	$8.8B
Repligen (RGEN)	$7.9B
Halozyme Therapeutics (HALO)	$7.8B